AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Lyra Therapeutics To Present at the Evercore ISI 2nd Annual HealthCONx Conference

November 26, 2019

WATERTOWN, Mass.--(BUSINESS WIRE)--Nov 26, 2019--

Lyra Therapeutics, Inc., a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat diseases, today announced that the company will present at the Evercore ISI 2nd Annual HealthCONx Conference.

Maria Palasis, Ph.D., Lyra’s President and Chief Executive Officer, will present an overview of the company, as part of a fireside chat presentation, on Tuesday, December 3, 2019, at 12:30 p.m. ET. The Evercore ISI 2nd Annual HealthCONx Conference will take place on December 3-5, 2019, in Boston, MA.

About Lyra Therapeutics

Lyra Therapeutics, Inc. is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat diseases. The company’s proprietary technology platform, XTreo™, is designed to precisely and consistently deliver medicines directly to the affected tissue for sustained periods with a single administration. The company’s initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis (CRS). The therapeutic embedded within LYR-210 and LYR-220 is mometasone furoate, which is the active ingredient in various FDA-approved drugs and has a well-established efficacy and safety profile. CRS is an inflammatory disease of the paranasal sinuses which leads to debilitating symptoms and significant morbidities and affects approximately 13 million people in the United States. The company is advancing LYR-210 as a potential preferred alternative to surgery in an ongoing Phase 2 clinical trial for CRS patients who have failed medical management. In its Phase 1 clinical trial, LYR-210 met its primary safety endpoint, and it was observed that patients generally experienced significant and rapid, clinically meaningful and durable improvement in SNOT-22 scores, an established patient symptom severity scale, through week 25, which was the end of the trial. The company is also developing LYR-220 for use in CRS patients who have an enlarged nasal cavity due to sinus surgery but continue to require treatment to manage CRS symptoms. Beyond CRS, the company believes its XTreo platform has potential applications in other disease areas, which it is actively exploring to further broaden the platform’s therapeutic potential.

View source version on businesswire.com:https://www.businesswire.com/news/home/20191126005114/en/

CONTACT: Media Contact:

Kathryn Morris

914-204-6412

kathryn@theyatesnetwork.comInvestor Contact:

Laurence Watts

619-916-7620

laurence@gilmartinir.com

KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS

INDUSTRY KEYWORD: BIOTECHNOLOGY OTHER HEALTH HEALTH PHARMACEUTICAL CLINICAL TRIALS

SOURCE: Lyra Therapeutics, Inc.

Copyright Business Wire 2019.

PUB: 11/26/2019 08:00 AM/DISC: 11/26/2019 08:01 AM

http://www.businesswire.com/news/home/20191126005114/en